Raptor Pharmaceutical Reports Third Quarter 2014 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Raptor Pharmaceutical Reports Third Quarter 2014 Financial Results and Provides Corporate Update

Global Net Product Sales for PROCYSBI ® of $23.8 Million for Third Quarter 2014
PROCYSBI Revenue of $52.2 Million Reached Through September
2014 PROCYSBI Revenue Guidance of $65-$70 Million Maintained
2014 Cash Operating Expense Guidance Narrowed to $80-$85 Million

Company to Host Conference Call and Webcast Today at 4:30 p.m. ET

NOVATO, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP ) reported financial results for the third quarter ended September 30, 2014 and provided an update on recent corporate developments.

Summary

Net product global sales for PROCYSBI ® for the quarter were $23.8 million compared to $6.6 million for the same period in 2013. Net product sales for PROCYSBI for the nine months ended September 30, 2014 were $52.2 million.

In the third quarter, Raptor transitioned to recognizing revenue when PROCYSBI is received by the specialty pharmacy channel from recognizing revenue when PROCYSBI shipment receipt is confirmed by the patient. In accordance with general practice and based on over one full year of U.S. PROCYSBI sales experience, the company believes it is able to reasonably estimate sales allowances and has begun recognizing revenue at the point of PROCYSBI sale to the specialty pharmacy. This change in timing of revenue recognition resulted in a one-time increase to PROCYSBI net product sales of $4.4 million in the third quarter.

Based on year-to-date results, the company maintains 2014 global net product sales guidance for PROCYSBI of $65 to $70 million.

Raptor now expects 2014 operating expenses, excluding stock option compensation expense, of $80 to $85 million, which is narrowed from $80 to $90 million on a non-GAAP basis.

Net loss on a non-GAAP cash basis was $2.5 million for the third quarter or $0.04 per share.

"We are pleased with the continued robust global commercial performance of PROCYSBI, which is a testament to our team's ability to penetrate and expand the market," said Julie Anne Smith, President and CEO-designate for Raptor Pharmaceutical. "In addition, we continue to advance our vibrant, value-creating product portfolio and look forward to continued progress in our long-term growth strategy."

Third Quarter 2014 Financial Highlights

Raptor provides non-GAAP financial measures, which it believes can enhance an overall understanding of its financial performance when considered together with GAAP figures. Refer to the section of this press release below entitled "Non-GAAP Financial Information" for a full discussion on this subject.

Net Product Sales

PROCYSBI net product sales for the third quarter of 2014 were $23.8 million, which includes a one-time accounting policy adjustment of $4.4 million, versus $6.6 million for the third quarter of 2013. Growth was driven by continued market penetration in both the U.S. and Germany. PROCYSBI became commercially available in the U.S. in mid-June 2013, in Germany in April 2014 and in Austria in August 2014.

Cost of Sales

Cost of sales were $3.9 million for the third quarter of 2014, which includes an inventory reserve, compared to $0.4 million for the third quarter of 2013.

Research & Development (R&D)

R&D expenses for the third quarter of 2014 were $9.0 million compared to $6.8 million for the third quarter of 2013. The increase was primarily due to increases in staffing, preclinical studies, clinical trials and non-commercial drug manufacturing expenses.

Selling, General and Administrative (SG&A)

SG&A expenses were $15.1 million for the third quarter of 2014 compared to $8.3 million for the third quarter of 2013. The increase was primarily due to additional sales and marketing costs associated with the commercialization of PROCYSBI in the U.S. and the establishment of our EU commercial headquarters and infrastructure.

Interest Expense

Interest expense for the third quarter of 2014 was $4.4 million compared to $2.3 million for the third quarter of 2013. The increase was due primarily to the $70.0 million of increased principal of the two debt agreements with HealthCare Royalty Partners effective July 1, 2014 and to the higher royalty interest on increased sales in the third quarter of 2014.

Net Loss

Non-GAAP net loss, which excludes stock-based compensation expense for the third quarter of 2014 was $2.5 million, or $0.04 per share, compared to a net loss of $15.5 million, or $0.26 per share, in the third quarter of 2013. GAAP net loss in the third quarter of 2014 was $6.0 million, or $0.10 per share, compared to a net loss of $17.3 million, or $0.29 per share, in the third quarter 2013.

Cash and Cash Equivalents

Raptor ended the third quarter with $114.7 million in cash and cash equivalents. In July 2014, Raptor closed a private placement of $70.0 million with HealthCare Royalty Partners and its affiliates. The funding included $60.0 million in new convertible senior notes and an additional $10 million of funding pursuant to an amended and restated loan agreement, originally signed on December 20, 2012.

2014 Financial Guidance

  • Maintaining 2014 global net product sales guidance for PROCYSBI of $65 to $70 million.
     
  • Narrowing 2014 cash operating expense guidance to $80 to $85 million from $80 to $90 million.

Product and Pipeline Updates

PROCYSBI for Nephropathic Cystinosis

  • To date, PROCYSBI has been sold outside of the U.S. to patients in Germany, Austria and Switzerland.

RP103 for Huntington's Disease (HD)

  • At the end of September, 47 patients completed the 36-month protocol and 100% of completing patients elected to enroll in the extension study.
     
  • Data from the 18-month analysis of an ongoing three-year Phase 2/3 clinical trial of RP103 (delayed release cysteamine) for the potential treatment of HD in collaboration with the Centre Hospitalier Universitaire d'Angers (CHU d'Angers) will be presented at the Huntington's Study Group Eighth Annual HD Clinical Research Symposium on Saturday, November 8 in Minneapolis, MN.
     
  • Raptor has recently met with the FDA and EMA for discussions on how to proceed with the clinical development of RP103 in HD.

RP103 for Pediatric Nonalcoholic Steatohepatitis (NASH)

  • In the CyNCH trial, approximately 100 of the 169 enrolled patients have completed the Week 52 visit. Over 90% of randomized patients remain in the study.
     
  • The last patient is expected to complete the treatment phase of the trial in January 2015, followed by the 26-week observation phase.

Anticipated Upcoming Milestones

  • 4Q 2014: Update from the late-onset nephropathic cystinosis screening project
     
  • 1H 2015: Filing for registration for PROCYSBI in Canada
     
  • 2015: Top-line Phase 2b RP103 data in pediatric NASH
     
  • 2015: Final results from the Phase 2/3 RP103 study in Huntington's disease
     
  • 2015: Regulatory update regarding RP103 in Huntington's disease
     
  • 2015: Interim Phase 1 RP103 data in Leigh syndrome

Conference Call and Webcast

Raptor will conduct a conference call and live audio webcast at 4:30 p.m. ET (1:30 p.m. PT) today.  The live call may be accessed by dialing (888) 346-9290 for domestic callers or (412) 902-4275 for international callers and using the conference ID number 10055102. A live webcast of the conference call will be available online from the investor relations section of the company website at www.raptorpharma.com . After the call, a webcast replay will be available on the Raptor website for 90 days. A telephone replay of the call will be available by dialing (877) 344-7529 for domestic callers, or (412) 317-0088 for international callers, and using the conference ID number 10055102.

Non-GAAP Financial Information and Other Disclosures

Raptor uses non-GAAP financial measures, such as non-GAAP net loss, non-GAAP net loss per share and non-GAAP operating expense, to assess and analyze its operational results and trends and to make financial and operational decisions. Raptor believes these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding Raptor's operating performance and exclude non-cash stock-based compensation expenses which fluctuate from period to period based on factors that are not within the company's control, such as the company's stock price. These non-GAAP financial measures should not be considered an alternative to measurements required by GAAP, such as net loss, net loss per share and total operating expense, and should not be considered measures of Raptor's liquidity. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations between non-GAAP financial measures and GAAP financial measures are included in the table accompanying this press release after the unaudited consolidated financial statements.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic steatohepatitis (NASH), Leigh syndrome and other mitochondrial diseases. With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. and EU. A request for orphan designation for Leigh syndrome has been submitted to the FDA. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson's disease and Rett syndrome. For additional information, please visit www.raptorpharma.com .

About PROCYSBI ® (cysteamine bitartrate) delayed-release capsules

PROCYSBI is a cystine depleting agent that is approved in the U.S. for the management of nephropathic cystinosis in adults and children ages 6 years and older. It is contraindicated in patients with a hypersensitivity to penicillamine. The most commonly reported side effects are vomiting, abdominal pain/discomfort, headaches, nausea, diarrhea, anorexia/decreased appetite, breath odor, fatigue, dizziness, skin odor and rash. For additional information on PROCYSBI, including full prescribing information, please visit www.procysbi.com .

FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are indicated by words or phrases such as "believes," "expects," "anticipates," "estimates," "plans," "continuing," "ongoing," "projected" and similar words or phrases and relate to future events or our future results of operations or future financial performance, including, but not limited to, statements regarding market expansion outside the U.S., Raptor's expected net product sales for PROCYSBI for 2014 , projected non-GAAP operating expenses for 2014 and volatility of the company's common stock price and its effect on stock-based compensation expense, the timing of clinical trial activities and results, the anticipated introduction of PROCYSBI in additional markets and the timing of that introduction and filing for approval in Canada and the timing of that filing. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the company's actual results to be materially different from these forward-looking statements. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Factors which may contribute to differences in actual results include, among others: market acceptance and sales of PROCYSBI in the U.S. and the EU; Raptor's ability to expand the use of RP103 and to receive regulatory approval for other indications; Raptor's reliance on a single active pharmaceutical ingredient supplier, a single third-party manufacturer and other third parties in connection with drug product development; compliance with healthcare regulations, ongoing regulatory requirements and potential penalties; any serious adverse side effects associated with PROCYSBI or any other future products and product liability claims; third-party payor coverage, reimbursement and pricing; enacted and future healthcare legislation; Raptor's ability to obtain and maintain orphan drug or other regulatory exclusivity for PROCYSBI or any other future products; the integration of European operations with U.S. operations; relationships with key scientific and medical collaborators; intellectual property protection and claims and continued license rights; and Raptor's ability to fund its operations and make required payments on its debt. Certain of these risks, uncertainties and other factors are described in greater detail in the company's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and consider, including: Raptor's annual report for the twelve months ended December 31, 2013 on Form 10-K filed with the SEC on March 17, 2014, quarterly reports for the quarterly period ended March 31, 2014 and June 30, 2014 on Form 10-Q filed with the SEC on May 9, 2014 and August 7, 2014, respectively, and other periodic reports filed with SEC, all of which are available free of charge on the SEC's web site at http://www.sec.gov . Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor's reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements except as may be required by law.

 
Raptor Pharmaceutical Corp.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands, except shares and per share data)
     
     
     
  September 30, 2014 December 31, 2013
ASSETS    
Current assets:    
Cash and cash equivalents  $ 114,678  $ 83,052
Restricted cash  894  500
Accounts receivable  10,479 6,181
Inventories  12,747  3,000
Prepaid expenses and other  4,464  3,566
Total current assets  143,262  96,299
Noncurrent assets:    
Fixed assets, net  5,602  1,810
Goodwill  3,275  3,275
Intangible assets, net  3,034  3,213
Other assets  6,196  4,129
Total Assets  $ 161,369  $ 108,726
     
LIABILITIES AND STOCKHOLDERS' EQUITY    
     
Current liabilities:    
Accounts payable  $ 3,376  $ 5,264
Accrued liabilities  19,560  13,128
Common stock warrant liability  654  7,066
Deferred revenue  --   4,698
Note payable, current portion  6,000  -- 
Total current liabilities  29,590  30,156
Noncurrent liabilities:    
Note payable, net of current portion  54,000  50,000
Convertible debt  60,000  -- 
Total liabilities  143,590  80,156
     
Stockholders' equity:    
Preferred stock, $0.001 par value per share, 15,000,000 shares
 authorized, zero shares issued and outstanding
 --   -- 
Common stock, $0.001 par value per share, 150,000,000 shares
 authorized, 63,268,534 and 61,614,576 shares issued and outstanding 
 at September 30, 2014 and December 31, 2013, respectively
 63  62
Additional paid-in capital  256,810  234,286
Accumulated other comprehensive loss  (122)  (423)
Accumulated deficit  (238,972)  (205,355)
Total stockholders' equity  17,779  28,570
Total Liabilities and Stockholders' Equity  $ 161,369  $ 108,726
 
Raptor Pharmaceutical Corp.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except shares and per share data)
         
         
  Three Months Ended
September 30,
Nine Months Ended
September 30,
  2014 2013 2014 2013
         
Net product sales  $ 23,764  $ 6,603  $ 52,211  $ 6,624
Cost of sales  3,917  442  6,226  867
Gross profit  19,847  6,161  45,985  5,757
         
Operating expenses:        
Research and development  9,001  6,791  29,625  21,418
Selling, general and administrative  15,077  8,334  40,468  25,576
Total operating expenses  24,078  15,125  70,093  46,994
         
Loss from operations  $ (4,231)  $ (8,964)  $ (24,108)  $ (41,237)
         
Interest income  14  3  54  174
Interest expense  (4,380)  (2,287)  (10,856)  (4,088)
Foreign currency transaction gain (loss)  5  15  42  (20)
Loss on short-term investments  --   --   --   (129)
Adjustment to fair value of common stock warrants  206  (6,044)  (1,091)  (12,025)
Other income  2,346  --   2,346  -- 
Net loss before provision for income taxes  (6,040)  (17,277)  (33,613)  (57,325)
Benefit from (provision for) income taxes  9  --   (4)  -- 
         
Net Loss  $ (6,031)  $ (17,277)  $ (33,617)  $ (57,325)
         
Other comprehensive gain (loss):        
Foreign currency translation adjustment  103  11  301  (78)
         
Comprehensive Loss  $ (5,928)  $ (17,266)  $ (33,316)  $ (57,403)
         
Net loss per share:        
Basic and diluted  $ (0.10)  $ (0.29)  $ (0.54)  $ (1.01)
         
Weighted-average shares outstanding:        
Basic and diluted  62,896,379  59,964,308  62,562,865  56,657,937
 
Raptor Pharmaceutical Corp.
Reconciliation of GAAP to Non-GAAP Financial Information
(Unaudited)
(In thousands, except shares and per share data)
         
         
  Three Months Ended
September 30,
Nine Months Ended
September 30,
  2014 2013 2014 2013
         
Net loss  $ (6,031)  $ (17,277)  $ (33,617)  $ (57,325)
         
Stock-based compensation expense  3,575  1,823  9,224  5,420
         
Non-GAAP Loss  $ (2,456)  $ (15,454)  $ (24,393)  $ (51,905)
         
Adjusted net loss per share:        
Basic and diluted  $ (0.04)  $ (0.26)  $ (0.39)  $ (0.92)
         
Weighted-average shares outstanding:        
Basic and diluted  62,896,379  59,964,308  62,562,865  56,657,937

Kimberly Lee, D.O. Vice President, Corporate Strategy and Communications (415) 408-6351 INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 MEDIA CONTACT: Cammy Duong Canale Communications (619) 849-5382

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 63

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand

Updated Category News Views 36

A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...

Continue Reading
Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 12

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 209

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Kendra Scott’s Dolly Tribute Tests Purposeful Luxury

Updated Category News Views 25

Butterflies, music notes, and a $70 pendant are carrying a surprisingly serious brand message this November. Kendra Scott’s new Dolly Parton Tribute Collection is plainly built to celebrate Dolly’s style, but it also shows how a consumer brand can make sentiment do some commercial heavy lifting without turning the whole thing into mush. The collection arrived November...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 95

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
American Pride Bank Tests a Fast Southeast Expansion

Updated Category News Views 0

Those old Winston-Salem smokestacks make a fitting backdrop for a bank trying to build something new, and American Pride Bank is moving with uncommon speed. Its new office at 450 N. Patterson Ave., Suite 200 sits in the Bailey South building in Innovation Quarter, across from Bailey Park and amid a district deliberately remade for founders, researchers and growing...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 141

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 70

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 115

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

AARP Maryland Celebrates Innovative Aging Support Initiative

Updated Category News Views 228

AARP Maryland Celebrates Innovative Aging Support Initiative AARP Maryland is thrilled to announce the launch of a remarkable initiative known as Longevity Ready Maryland. This initiative represents a pivotal 10-year plan that aims to coordinate services and policies tailored for the state's older adults. AARP, which has over 850,000 members in Maryland, recognizes the...

Continue Reading
Evaluating Fairness: Logility’s Tender Offer Under Scrutiny

Updated Category News Views 180

Logility Supply Chain Solutions Under Investigation Recent developments have emerged concerning Logility Supply Chain Solutions, Inc. as Ademi & Fruchter LLP embarks on an investigation. The focus of this inquiry is whether the company, publicly traded on Nasdaq under the ticker LGTY, is providing a fair price to its shareholders amidst their ongoing transaction with...

Continue Reading
Exciting Developments at J.F. Lehman & Company in 2025

Updated Category News Views 422

Significant Changes at J.F. Lehman & Company J.F. Lehman & Company, a prominent player in the private investment sector, is making waves in the investment community with exciting promotions and new team members. This strategic movement is pivotal for the firm as it focuses on sectors like aerospace, defense, maritime, government, and environmental industries. Celebrating...

Continue Reading
Westland Mall Engages Community During Hispanic Heritage Month

Updated Category News Views 324

Let’s dive into the scene at Westland Mall. This place isn’t just your average shopping center; it’s a heartbeat of the community, especially when they ramp up for Hispanic Heritage Month. The mall is leaning hard into this celebration, showcasing the rich tapestry of Hispanic culture that colors its locality. Cultural Celebration Galore The initiative isn’t...

Continue Reading
Pro Music Rights Gains Official Approval as PRO in US Market

Updated Category News Views 198

Pro Music Rights Officially Recognized as a Performing Rights Organization Music Licensing, Inc. (OTC: SONG) has recently celebrated a significant milestone with the official recognition of its wholly-owned subsidiary, Pro Music Rights (PMR), as a Performing Rights Organization (PRO). This acknowledgment, appearing in the Federal Register, elevates PMR’s status in the...

Continue Reading